Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMasuho SaburiNANobuyuki AotsukaHYHiroki Yokoyama

Discussion

Loading...

Member takes

Overview

Single-arm trial shows 36.6% treatment-free remission in chronic myeloid leukemia after ponatinib, suggesting further evaluation needed.

Cite This Study

Saburi et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e41ahttps://doi.org/10.1182/blood-2025-5546
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the <scp>Japan Adult Leukemia Study Group RE</scp> ‐ <scp>STOP219</scp> study2026 · 1 citations
  2. 2Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response2025
  3. 3Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors2025
  4. 4Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI2025 · 1 citations
  5. 5Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-00032025